No abstract

No abstract

No abstract

After 54 weeks, as add-on therapy to metformin, once-weekly omarigliptin was generally well tolerated and non-inferior to glimepiride in improving glycemic control, with a lower incidence of hypoglycemia and with weight loss vs weight gain.

Methods: Patients with advanced unresectable HCC received Lenvatinib 8 mg/ d regardless of patient body weight and anti-PD-1 antibody either q2wk (nivolumab or camrelizumab) or q3wk (pembrolizumab, sintilimab or toripalimab). Patients who completed at least one efficacy and safety assessment were eligible for this study. High-dimensional single-cell mass cytometry (CyTOF) and a bioinformatics pipeline for the in-depth characterization of the immune cell subsets was used to identify T cell subsets in the peripheral blood of patients before the treatment.Results: From May 2019 to Dec. 2019, we recruited 15 patients. All the patients are assessable for efficacy. Two patients achieved complete response (CR), 7 patients achieved partial response (PR), and 6 patients achieved progressing disease (PD) per mRECIST. CyTOF identified 36 meta-clusters contained all of the major immune cell populations such as T cells, B cells, NK cells, DC cells and momocytes with a panel of 42 antibodies. Moreover, we delineated an PD1 mid KLRG1 + Tbet high effector memory T cell phenotype that was significantly more abundant in responders (CR or PR, n¼9) to combined therapy compared with non-responders (n¼6) (PD, P < 0.05).Conclusions: PD1 mid KLRG1 + Tbet high effector memory T cell in the peripheral blood may be a useful biomarker for predicting tumor response to the combination therapy in HCC.Legal entity responsible for the study: The authors.